Damian Clarke-Bruce
Algemeen Directeur bij HaemaLogiX Pty Ltd.
Vermogen: 6 711 $ op 31-05-2024
Profiel
Damian Clarke-Bruce is currently the Chief Executive Officer & Managing Director at HaemaLogiX Pty Ltd.
He was previously the Chief Executive Officer, MD & Director at Race Oncology Ltd.
and the Executive Director-Global Marketing at Pharming Group NV.
Mr. Clarke-Bruce has an undergraduate degree from The University of New South Wales, a graduate degree from Macquarie University, and a graduate degree from The University of Sydney.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
RACE ONCOLOGY LTD.
0.00% | 21-08-2023 | 6 818 ( 0.00% ) | 6 711 $ | 31-05-2024 |
Actieve functies van Damian Clarke-Bruce
| Bedrijven | Functie | Begin |
|---|---|---|
HaemaLogiX Pty Ltd.
 HaemaLogiX Pty Ltd. BiotechnologyHealth Technology HaemaLogiX Pty Ltd. is a biotech company located in Sydney, Australia. The Australian company has a wide range and depth of experience in antibody research, nonclinical & clinical development, manufacturing, and commercialization. The scientific advisory board members are internationally recognized experts in monoclonal antibody therapies and hematology. The company's current research and clinical trial partners are leaders in multiple myeloma and AL amyloidosis therapy. Founded in 2014, the company is researching immune-based treatments such as monoclonal antibodies, CAR T cell therapies, and bispecific antibodies to target unique antigens on malignant cells and improve the quality of life of patients suffering from blood cancers like multiple myeloma and other life-threatening diseases like AL amyloidosis. Bryce D. Carmine has been the CEO of the company since 2015. | Algemeen Directeur | 13-11-2023 |
Eerdere bekende functies van Damian Clarke-Bruce
| Bedrijven | Functie | Einde |
|---|---|---|
| RACE ONCOLOGY LIMITED | Algemeen Directeur | 22-08-2023 |
| PHARMING GROUP N.V. | Verkoop & Marketing | 01-01-2023 |
Opleiding van Damian Clarke-Bruce
| The University of New South Wales | Undergraduate Degree |
| Macquarie University | Graduate Degree |
| The University of Sydney | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| RACE ONCOLOGY LIMITED | Health Technology |
| PHARMING GROUP N.V. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
HaemaLogiX Pty Ltd.
HaemaLogiX Pty Ltd. BiotechnologyHealth Technology HaemaLogiX Pty Ltd. is a biotech company located in Sydney, Australia. The Australian company has a wide range and depth of experience in antibody research, nonclinical & clinical development, manufacturing, and commercialization. The scientific advisory board members are internationally recognized experts in monoclonal antibody therapies and hematology. The company's current research and clinical trial partners are leaders in multiple myeloma and AL amyloidosis therapy. Founded in 2014, the company is researching immune-based treatments such as monoclonal antibodies, CAR T cell therapies, and bispecific antibodies to target unique antigens on malignant cells and improve the quality of life of patients suffering from blood cancers like multiple myeloma and other life-threatening diseases like AL amyloidosis. Bryce D. Carmine has been the CEO of the company since 2015. | Health Technology |
